AnalysisPolicySeptember 16, 2026

Guest post argues AI superforecasting could reshape FDA drug review

ACX grantee Josh Morrison of 1DaySooner argues cheap AI superforecasters could replace the FDA's case-by-case human judgment with clearer standards companies can meet. He says medicine's complexity and high stakes let pharma loophole-trawl any objective rule, so firms err toward caution.

1 source

More stories today

Open the live feed